New drug duo aims to outperform standard care in Hard-to-Treat stomach cancer

NCT ID NCT06346197

First seen Nov 18, 2025 · Last updated May 06, 2026 · Updated 23 times

Summary

This phase 3 study compares a new two-drug immunotherapy (botensilimab + balstilimab) against the current standard treatment (chemotherapy plus nivolumab) in people with advanced or metastatic stomach or esophageal cancer that has a specific genetic feature (MSI-H/dMMR). The goal is to see if the new combination helps patients live longer. About 132 adults whose tumors have not been treated before will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Brest

    RECRUITING

    Brest, 29000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • CHU de Poitiers

    RECRUITING

    Poitiers, 86000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69008, France

    Contact Email: •••••@•••••

  • Hôpital Privé Jean Mermoz

    RECRUITING

    Lyon, 69008, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Mutualiste Montsouris

    RECRUITING

    Paris, 75000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut Paoli Calmettes

    RECRUITING

    Marseille, 13000, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.